FIXX | Homology Medicines, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.9000 - 0.9725
52 Week Range	0.9000 - 26.64
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	401,467
Average Volume	29,535
Shares Outstanding	3,229,640
Market Cap	3,018,745
Sector	Healthcare
Industry	Biotechnology
IPO Date	2018-03-28

Valuation
Profitability
Growth
Health
P/E Ratio	-0.03
Forward P/E Ratio	N/A
EPS	-35.10
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	7
Country	USA
Website	FIXX

Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing for various genetic disorders. The company's various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, bone marrow, cardiac and skeletal muscle, and eye. Its lead product candidate is HMI-102, which is in Phase 2 pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; HMI-202 to treat metachromatic leukodystrophy; and HMI-203 for the treatment of mucopolysaccharidosis type II, as well as HMI-104 for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.

FIXX's peers: ACET, ACIU, ADAP, ADCT, ADVM, AGIO, ALEC, ALVR, ARCT, BCYC, BDTX, CABA, CAPR, CDMO, CLDX, COGT, CORT, DNLI, FDMT, FGEN, CMPX, GBIO, GOSS, IDYA, IPSC, KOD, KROS, LRMR, MESO, MGTX, MTNB, NAUT, OMER, PASG, PHAR, PSTX, QSI, RVMD, SRRK, STOK, STRO, SYRS, TCRT, TNYA, TSHA, TVTX, UBX, VCYT, VRCA, XENE, XNCR

*Chart delayed

Analyzing fundamentals for FIXX we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is bad and Health is weak. For more detailed analysis please see FIXX Fundamentals page.

Watching at FIXX technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, but short-term trend is bullish. More technicals details can be found on FIXX Technicals page.